DE

Dottikon Es Holding AGSWX Dottikon Es Stock Report

Last reporting period 31 Mar, 2024

Updated 05 Nov, 2024

Last price

Market cap $B

4.132

Middle

Exchange

XSWX - Six Swiss Exchange

DESN.SW Stock Analysis

DE

Neutral

Based on Eyestock quantitative analysis, DESN.SW`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

91/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-5.0 %

Overvalued

Market cap $B

4.132

Dividend yield

Shares outstanding

13.809 B

Dottikon ES Holding AG engages in the development and manufacture of chemicals, intermediates, and pharmaceutical ingredients. The company is headquartered in Dottikon, Aargau and currently employs 670 full-time employees. The company went IPO on 2005-03-31. Its product range includes active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, as well as industrial chemicals. Its pharmaceutical products can be found in medications for, among others, heart disease, asthma, high blood pressure and ulcers. Dottikon ES Holding AG's industrial end products include food additives, cosmetics, electro-chemicals, photo-chemicals and agricultural chemicals. The firm also offers distillation plants and thin layer evaporators for the recycling of solvents, as well as high temperature incinerators for the waste treatment of hazardous waste. As of March 31, 2012, the Company had two wholly owned subsidiaries: DOTTIKON EXCLUSIVE SYNTHESIS AG and DOTTIKON ES MANAGEMENT AG. The company also held a 33.9%-stake in SYSTAG, System Technik AG.

View Section: Eyestock Rating